Drug profile · INN
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
CHONDROCELECT
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins (CHONDROCELECT) is a somatic cell supplemental therapy.
Drug details — characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
- Class
- Musculo-skeletal system (M09)
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.83
Quick answer
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins (CHONDROCELECT) is a somatic cell supplemental therapy.
Key facts
Mechanism of action
Somatic cell supplemental therapy
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins?
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins (CHONDROCELECT) is a somatic cell supplemental therapy.
What is the brand name for characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins?
CHONDROCELECT is a marketed brand name for characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins. Check FDA Drugs@FDA for the current US label holder and prescribing information.